Should Biogen Stock Holders Look At Amgen Instead?

BIIBYTD+42.9%SPYYTD+7.9%XLVYTD+18.5%
Analyze BIIB →

Today’s big story: Could Anthropic Stock Fall 25%?

Investors own both Biogen (BIIB) and Amgen for a single bet: newer drugs taking over from older ones. Amgen is further along, since its six key growth drivers, including Repatha, made up over 70% of its third-quarter product sales. Biogen’s growth drugs, including SPINRAZA, already make up about 63% of its core pharmaceutical revenue. But they still have to lift the company’s total sales and profit. So are those newer drugs lifting Biogen’s total sales yet?

Image from Pixabay

Biogen’s Total Sales Are Only Starting To Grow

So far, the lift is largest in the latest quarter. Biogen’s revenue rose 10.6% in the third quarter of 2026 from a year earlier. Management said the Appellis acquisition supported that jump. Over the past 12 months, Biogen’s revenue grew just 2.3%, against 8.2% for Amgen.

Biogen’s sales grew just 2.3% over the past 12 months, against 8.2% for Amgen. Waiting for that to speed up means holding a stock that pays you no dividend. Meanwhile, the Trefis Income Solution pays a dividend yield about 3x the S&P 500’s, from 50 stocks with at least 10 straight years of dividends. See what it pays.

Biogen’s growth drugs brought in about $1.3 billion in the third quarter, up 49% from a year earlier. Management said part of that total came from one-time doses for SPINRAZA patients moving to a higher dose.

The two companies’ latest forecasts are different kinds of news. On November 3, Amgen raised its 2026 revenue forecast to a midpoint of $39.3 billion, from $38.8 billion. On October 28, Biogen raised the low end of its 2026 adjusted earnings forecast, giving a range of $12.20 to $13.00 per share. Management said faster savings from combining with Appellis mean the deal will cut less from 2026 earnings than it expected. So Amgen’s raise is about selling more, while Biogen’s rests partly on the deal it made.

Amgen’s Margin Widened While Biogen’s Shrank

Biogen’s profit has not recovered yet. Its operating margin stood at 17.6% over the past 12 months, down sharply from a year earlier. Amgen’s margin moved the other way, climbing to 32.4% from 24.1%.

In the third quarter alone, Biogen booked $284 million of charges for acquired research and milestones. Management said those charges pushed its GAAP result to a loss of $0.14 per share.

Biogen expects the Appellis deal to add to its adjusted earnings per share in 2027. The company has repaid $600 million of the loans it took for the deal. It plans to repay the remaining $1.4 billion by the end of 2027.

Biogen Stock Costs More On Earnings, Less On Sales

Biogen stock trades at 106.9 times its earnings over the past 12 months, against 25.6 for Amgen. Biogen’s P/E is based on a thin year of profit, with a net margin of 3.4% over the same 12 months.

On sales, the order flips. Biogen trades at 3.6 times sales, against 6.2 for Amgen.

A Biogen holder also gives up income while waiting. Biogen pays no dividend, while Amgen’s dividend yield is 2.2%. So while they wait for sales and profit to grow, Biogen holders collect nothing.

Amgen Comes Out Ahead On More Measures

Amgen’s revenue growth averaged 13.3% across the last three 12-month periods, against 1.1% for Biogen. Amgen also carries the wider operating margin and the lower P/E.

Biogen’s edges are its cheaper sales multiple and a debt load close to Amgen’s. Its total debt equals 21.0% of its market value, against 22.5% for Amgen.

Biogen’s total sales have started to grow, but much of the lift came from SYFOVRE and Empaveli, the two drugs it bought with Appellis. Its profit has not recovered yet. Biogen is expected to report in February 2027. That report will show its operating margin for all of 2026.

Two careful investors can read these same figures and still pick differently. That is why the method behind a pick matters as much as the pick.

Found A Better Strategy? We’d Love To Learn.

Ours is the Trefis High Quality (HQ) Portfolio: 30 quality stocks in equal weight. Since its September 2020 launch it has returned more than 105%, ahead of a benchmark that combines the S&P 500, S&P MidCap and Russell 2000. If yours has done better, tell us about it. If not, come take a look.

See The HQ Portfolio

Spot an error or want more like this? Tell us in 10 seconds.